Insider Selling: Avantor, Inc. (NYSE:AVTR) EVP Sells 3,758 Shares of Stock

Avantor, Inc. (NYSE:AVTR) EVP James Bramwell sold 3,758 shares of Avantor stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $17.53, for a total value of $65,877.74. Following the completion of the transaction, the executive vice president now owns 87,379 shares of the company’s stock, valued at approximately $1,531,753.87. This trade represents a 4.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Avantor Trading Up 1.3 %

Shares of NYSE AVTR opened at $16.71 on Friday. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54. The business has a fifty day simple moving average of $20.51 and a two-hundred day simple moving average of $22.69. The firm has a market cap of $11.37 billion, a PE ratio of 16.06, a price-to-earnings-growth ratio of 1.55 and a beta of 1.28. Avantor, Inc. has a twelve month low of $16.41 and a twelve month high of $28.00.

Avantor (NYSE:AVTR) last issued its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same quarter last year, the firm posted $0.22 earnings per share. Analysts expect that Avantor, Inc. will post 1.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on AVTR shares. UBS Group reiterated a “neutral” rating and issued a $25.00 target price (down previously from $29.00) on shares of Avantor in a report on Friday, January 17th. Barclays dropped their target price on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Wells Fargo & Company dropped their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Stifel Nicolaus dropped their target price on Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a report on Monday, February 10th. Finally, Royal Bank of Canada decreased their price target on Avantor from $33.00 to $31.00 and set an “outperform” rating for the company in a research note on Monday, February 10th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Avantor currently has an average rating of “Moderate Buy” and a consensus target price of $25.92.

Institutional Investors Weigh In On Avantor

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Avantor during the 4th quarter valued at $5,712,000. American Trust raised its position in Avantor by 4.5% during the 4th quarter. American Trust now owns 15,198 shares of the company’s stock valued at $320,000 after purchasing an additional 658 shares in the last quarter. Mackenzie Financial Corp raised its position in shares of Avantor by 33.0% in the 4th quarter. Mackenzie Financial Corp now owns 43,358 shares of the company’s stock worth $914,000 after acquiring an additional 10,764 shares in the last quarter. Forum Financial Management LP bought a new position in shares of Avantor in the 4th quarter worth $417,000. Finally, Toronto Dominion Bank raised its position in shares of Avantor by 6.9% in the 4th quarter. Toronto Dominion Bank now owns 88,812 shares of the company’s stock worth $1,871,000 after acquiring an additional 5,748 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.